Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit

Carcinogenesis

Volumn 36, Issue 9, 2015, Pages 937-945

  Zhang, Zhenfeng ^a   Zhang, Shengzhe ^b   Ma, Pengfei ^a   Jing, Ying ^a   Peng, Huixin ^a   Gao, Wei Qiang ^a,b   Zhuang, Guanglei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIN28B PROTEIN; MICRORNA; MICRORNA 125A 5P; RNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; LIN28B PROTEIN, HUMAN; MIRN125 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BIOGENESIS; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; ANIMAL; BAGG ALBINO MOUSE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 84940663410     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv085     Document Type: Article

References (49)

1. Eggermont, A.M. et al. (2014) Cutaneous melanoma. Lancet, 383, 816-827.
2. Lawrence, M.S. et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 214-218.
3. Garraway, L.A. et al. (2013) Lessons from the cancer genome. Cell, 153, 17-37.
4. Chapman, P.B. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 364, 2507-2516.
5. Sosman, J.A. et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med., 366, 707-714.
6. Flaherty, K.T. et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med., 367, 1694-1703.
7. Lito, P. et al. (2013) Tumor adaptation and resistance to RAF inhibitors. Nat. Med., 19, 1401-1409.
8. Holderfield, M. et al. (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer, 14, 455-467.
9. Kemper, K. et al. (2014) Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res., 74, 5937-5941.
10. Ha, M. et al. (2014) Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol., 15, 509-524.
11. Li, Z. et al. (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov., 13, 622-638.
12. Bennett, P.E. et al. (2013) miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol. Genomics, 45, 1049-1059.
13. Kunz, M. (2013) MicroRNAs in melanoma biology. Adv. Exp. Med. Biol., 774, 103-120.
14. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
15. Ryan, B.M. et al. (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer, 10, 389-402.
16. Croce, C.M. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 10, 704-714.
17. Roush, S. et al. (2008) The let-7 family of microRNAs. Trends Cell Biol., 18, 505-516.
18. Büssing, I. et al. (2008) let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med., 14, 400-409.
19. Sampson, V.B. et al. (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res., 67, 9762-9770.
20. Johnson, S.M. et al. (2005) RAS is regulated by the let-7 microRNA family. Cell, 120, 635-647.
21. Lee, Y.S. et al. (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev., 21, 1025-1030.
22. Mayr, C. et al. (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315, 1576-1579.
23. Thornton, J.E. et al. (2012) How does Lin28 let-7 control development and disease? Trends Cell Biol., 22, 474-482.
24. Viswanathan, S.R. et al. (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet., 41, 843-848.
25. Viswanathan, S.R. et al. (2010) Lin28: A microRNA regulator with a macro role. Cell, 140, 445-449.
26. Beachy, S.H. et al. (2012) Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma. Blood, 120, 1048-1059.
27. Molenaar, J.J. et al. (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet., 44, 1199-1206.
28. Nguyen, L.H. et al. (2014) Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell, 26, 248-261.
29. Urbach, A. et al. (2014) Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev., 28, 971-982.
30. Fu, X. et al. (2014) miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene, 33, 4296-4306.
31. Schultz, J. et al. (2008) MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res., 18, 549-557.
32. Nemlich, Y. et al. (2013) MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest., 123, 2703-2718.
33. Lewis, B.P. et al. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.
34. Diskin, S.J. et al. (2012) Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat. Genet., 44, 1126-1130.
35. Liang, L. et al. (2010) MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology, 52, 1731-1740.
36. Cerami, E. et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov., 2, 401-404.
37. Gao, J. et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, pl1.
38. Cline, M.S. et al. (2013) Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci. Rep., 3, 2652.
39. Heo, I. et al. (2008) Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol. Cell, 32, 276-284.
40. Newman, M.A. et al. (2008) Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA, 14, 1539-1549.
41. Rybak, A. et al. (2008) A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat. Cell Biol., 10, 987-993.
42. Viswanathan, S.R. et al. (2008) Selective blockade of microRNA processing by Lin28. Science, 320, 97-100.
43. van Dongen, S. et al. (2008) Detecting microRNA binding and siRNA offtarget effects from expression data. Nat. Methods, 5, 1023-1025.
44. Kumar, M.S. et al. (2014) HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature, 505, 212-217.
45. Onichtchouk, D. et al. (1999) Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature, 401, 480-485.
46. Wu, L. et al. (2005) Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol. Cell. Biol., 25, 9198-9208.
47. Zhong, X. et al. (2010) Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J. Biol. Chem., 285, 41961-41971.
48. Xu, W.P. et al. (2013) Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma. Hepatology, 58, 1977-1991.
49. Piskounova, E. et al. (2011) Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell, 147, 1066-1079.